Three Patients Dropped Out of Alnylam's Phase II Trial for Revusiran

Alnylam Pharmaceuticals (NASDAQ:ALNY) reported earnings Thursday, but with no drugs on the market, the focus was on the pipeline -- and, unfortunately, potential problems therein. As part of its earnings press release, Alnylam disclosed that three patients discontinued from the revusiran phase 2 open label extension, or OLE, study due to injection-site reactions. The OLE is designed to allow patients in the phase 2 study to continue to receive the drug after they complete the initial study, and allows the company to capture long-term treatment data.

Help employers find you! Check out all the jobs and post your resume.